Li Jianxia, Deng Yanhong, Wang Jianping
Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Jun 25;21(6):627-631.
Rectal cancer is one of the most common malignancies in China. Total mesorectal excision (TME) plus neoadjuvant therapy is the standard treatment for locally advanced rectal cancer. After a development of over 20 years, neoadjuvant synchronous chemoradiotherapy has become the standard treatment and cornerstone of neoadjuvant therapy for rectal cancer. However, radiotherapy does not really increase the overall survival and is associated with long-term impact on the functions of anus, sex, urinary system and fertility, so the application of simple neoadjuvant chemotherapy rises gradually and becomes a potentially better treatment option. This paper elaborates the reason, present research status and future trend of the rising neoadjuvant chemotherapy.
直肠癌是中国最常见的恶性肿瘤之一。全直肠系膜切除术（TME）联合新辅助治疗是局部晚期直肠癌的标准治疗方法。经过20多年的发展，新辅助同步放化疗已成为直肠癌新辅助治疗的标准治疗方法和基石。然而，放疗并不能真正提高总体生存率，且会对肛门、性功能、泌尿系统和生育功能产生长期影响，因此单纯新辅助化疗的应用逐渐兴起，并成为一种潜在的更好的治疗选择。本文阐述了新辅助化疗兴起的原因、目前的研究现状及未来趋势。
